Literature DB >> 1509404

Beta 2-glycoprotein I deficiency and the risk of thrombosis.

L F Bancsi1, I K van der Linden, R M Bertina.   

Abstract

beta 2-glycoprotein I (beta 2-GP I) is a plasma protein with a high affinity for negatively charged surfaces. In vitro this protein shows a variety of anticoagulant properties (inhibition of contact activation and platelet dependent prothrombinase activity). Therefore we studied the possibility that a hereditary beta 2-GP I deficiency is a risk factor for (familial) thrombophilia. Plasma beta 2-GP I levels were measured in healthy volunteers and four different groups of patients with (familial) thrombophilia. In these 5 groups the prevalence of beta 2-GP I deficiency (i.e. beta 2-GP I antigen less than 77%) was found to be very similar (6.8-12.5%) and statistically not significantly different. This observation suggests that beta 2-GP I deficiency in itself is not a risk factor for thrombosis. One thrombophilic patient was found to be homozygous deficient of beta 2-GP I. The transmission of the defect in his family followed autosomal inheritance. One of his brothers was also homozygous deficient and at the age of 35 years still free of thromboembolic complications. The possibility that beta 2-GP I deficiency could be an additional risk factor for the development of thrombophilia in families with protein C deficiency was evaluated in a panel of 70 unrelated patients with clinically dominant protein C deficiency. The prevalence of beta 2-GP I deficiency in this group of patients (12.8%) was very similar to that in other groups of normals and patients. Moreover, there was no difference in the frequency of beta 2-GP I deficiency in symptomatic and asymptomatic protein C deficient patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1509404

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

Review 2.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Antiphospholipid syndrome.

Authors:  M Greaves
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

4.  Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.

Authors:  D M Keeling; A J Wilson; I J Mackie; D A Isenberg; S J Machin
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

5.  Low serum lipoprotein(a) and beta 2-glycoprotein I levels in HIV-1-positive hemophiliacs.

Authors:  J Matsuda; N Saitoh; K Gohchi; M Gotoh; M Tsukamoto
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

6.  Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids.

Authors:  M I Kamboh; D R Wagenknecht; J A McIntyre
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

Review 7.  Antiphospholipid syndrome: genetic review.

Authors:  Bahram Namjou
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

8.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Authors:  T Atsumi; M A Khamashta; O Amengual; S Donohoe; I Mackie; K Ichikawa; T Koike; G R Hughes
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 9.  The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it?

Authors:  Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

10.  Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome.

Authors:  Alexey Kolyada; Andrew Porter; Natalia Beglova
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.